The Mounjaro™ Quick Pen is a user-friendly, prefilled autoinjector designed for the subcutaneous administration of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is prescribed for adults with type 2 diabetes to improve glycemic control, often alongside diet and exercise. Tirzepatide offers a unique mechanism that targets two key incretin hormones, enhancing insulin secretion and reducing glucagon levels in a glucose-dependent manner.

Features

• Prefilled, disposable pen: No need for manual dosing or cartridge replacement.

• Once-weekly dosing: Designed for once-weekly injection, simplifying diabetes management.

• Hidden needle: The needle is concealed before, during, and after injection, reducing injection anxiety.

• Push-button activation: A simple push initiates the dose delivery with audible and tactile feedback.

• Dose selector window: Displays dose strength clearly, minimizing dosing errors.

• Compact design: Lightweight and portable for convenience.

Usage Instructions

• Remove the pen cap.

• Select the prescribed dose if the pen is adjustable (some versions are fixed-dose).

• Clean the injection site (abdomen, thigh, or upper arm).

• Press the pen firmly against the skin at a 90-degree angle.

• Press the injection button and hold until the dose delivery is complete (indicated by the dose window or an audible click).

• Dispose of the pen in a sharps container.

Storage and Handling

• Store refrigerated at 2°C to 8°C (36°F to 46°F).

• Do not freeze.

• Allow the pen to reach room temperature before injection (about 30 minutes).

• Protect from light.

Safety and Precautions

• Not for use in patients with type 1 diabetes or diabetic ketoacidosis.

• Monitor for signs of pancreatitis.

• Use with caution in patients with a history of thyroid tumors.

• Common side effects include nausea, vomiting, diarrhea, decreased appetite, and injection site reactions.

• Inform healthcare provider of any other medications or medical conditions.The Mounjaro™ Quick Pen is a user-friendly, prefilled autoinjector designed for the subcutaneous administration of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is prescribed for adults with type 2 diabetes to improve glycemic control, often alongside diet and exercise. Tirzepatide offers a unique mechanism that targets two key incretin hormones, enhancing insulin secretion and reducing glucagon levels in a glucose-dependent manner.

  Features

  • Prefilled, disposable pen: No need for manual dosing or cartridge replacement.

  • Once-weekly dosing: Designed for once-weekly injection, simplifying diabetes management.

  • Hidden needle: The needle is concealed before, during, and after injection, reducing injection anxiety.

  • Push-button activation: A simple push initiates the dose delivery with audible and tactile feedback.

  • Dose selector window: Displays dose strength clearly, minimizing dosing errors.

  • Compact design: Lightweight and portable for convenience.

  Usage Instructions

  • Remove the pen cap.

  • Select the prescribed dose if the pen is adjustable (some versions are fixed-dose).

  • Clean the injection site (abdomen, thigh, or upper arm).

  • Press the pen firmly against the skin at a 90-degree angle.

  • Press the injection button and hold until the dose delivery is complete (indicated by the dose window or an audible click).

  • Dispose of the pen in a sharps container.

  Storage and Handling

  • Store refrigerated at 2°C to 8°C (36°F to 46°F).

  • Do not freeze.

  • Allow the pen to reach room temperature before injection (about 30 minutes).

  • Protect from light.

  Safety and Precautions

  • Not for use in patients with type 1 diabetes or diabetic ketoacidosis.

  • Monitor for signs of pancreatitis.

  • Use with caution in patients with a history of thyroid tumors.

  • Common side effects include nausea, vomiting, diarrhea, decreased appetite, and injection site reactions.

  • Inform healthcare provider of any other medications or medical conditions.